Sean Fanning

Androgen Metabolism in Prostate Cancer: Recent Advances Abstract. Androgen biosynthesis is physiologically necessary for generating the principal stimulus for androgen receptor (AR) signaling and thus plays an e

Androgen Metabolism in Prostate Cancer: Recent Advances #metabolism #testosterone #prostatecancer url: academic.oup.com/endo/article...

🎯 We are so thrilled our new paper @narjournal.bsky.social is out! Fantastic collab with the labs of Gordon Hager NIH & Franck Dequiedt. Heaviest lifting from Greg Fettweiss, Kaustub Wagh, Diana Stavreva & Alba Jiménez-Panizo. Big thanks to Andrea Alegre-Marti JdC 🥳✨️
academic.oup.com/nar/article/...

📢 Read our new bioRx in colab with Gordon Hager NIH @PabloFuentesP #FRecio @aguslafuent @PresmanLab @WaghKaustubh #IGoldstein et al where we found glucocorticoid receptor GR self-assembly, chromatin binding & activity is modulated by bile acids binding to a novel druggable site

Allosteric Induction of Estrogen Receptor Ligand Binding Domain Tetramerization by a Distinct Complete Estrogen Receptor Antagonist Complete estrogen receptor antagonists (CERANs) are effective against advanced estrogen receptor-positive (ER+) breast cancers, but current chemical scaffolds limit our ability to explore the full ran...

Latest publication from our lab! A part of our ongoing efforts to identify estrogen receptor ligands that influence structural and oligomeric states in unique ways. pubs.acs.org/doi/10.1021/...

Right in time for the holidays!

As of today, we can confirm that we will be rescheduling all October and November grant application submission deadlines (specific dates to be announced in a future Notice). By delaying due dates that occurred both during the lapse in funding and in the week following, applicants will have access to NIH staff and the help desks as they develop their applications. Peer review meetings that were scheduled to take place between October 1 and November 14 have been cancelled and will be rescheduled, details to come. Additionally, council meetings that were scheduled to take place between October 1 and November 14 were cancelled and will be rescheduled, details to come.

grants.nih.gov/grants/guide...

This is going to be a fun next few grant cycles....

🔊 Nova publicació del Dpt @bqbiomedmolub.bsky.social pel grup liderat per la Dra Eva Estébanez-Perpiñá ‪@estebanezlab.bsky.social ‬@ibub-ub.bsky.social @biologiaub.bsky.social
Enhorabona! 👋👋

I know & trust that NIH staff will get this round of reviews done. Yet having done my own CSR reviews 'for nothing' & with my own R01 sitting unreviewed now, working on another NIH grant has never felt so painful and futile. A quiet impact on science, perhaps, robbing the joy from looking ahead.

Democracy in action, Illinois.

Proud of our state for peacefully showing up and speaking out together in one voice to fight back against Donald Trump’s takeover of our democracy.

Just wrapped up my medical school teaching for the year. I happened to have an exceptionally awesome group of M1s. I’m excited to see where they’ll go from here!

Meanwhile, when the dean utters his refrain, “Thank you for all your hard work,” the faculty will simply hear, “Sorry, we have no money to pay you.”

RFK Jr. and Trump tell us they want to Make America Healthy Again.

Great slogan. I agree. Unfortunately, they are doing the exact opposite.

Vaccines work. They are safe. They save lives.

No more conspiracy theories.  Kennedy must resign.

Fanning Lab BBQ 2025! Another good year in the books thanks to this exceptional group! Also, they wanted me to make ribs and brisket, they know I look for any excuse to do a cook.

You all were well represented!

Finally, I really enjoyed the opportunity to explore San Francisco more. Alcatraz was an eye opening experience, being a Chicago guy, I had to find the place that kept Capone.

I was also fortunate to have one of my proposed sessions take place on the latest in hormone-dependent cancers, which featured a fantastic story from Dan Frigo on metabolism in prostate cancer.

I had a wonderful time at Endo2025, catching up with great colleagues doing fantastic and important work in endocrinology. I particularly enjoyed chairing the session on Nuclear Receptor Structural Biology where @dougkojetin.bsky.social gave a powerhouse performance! 1/3

New review from us on radiation in #lobular breast cancer!
www.nature.com/articles/s41...

Lots of anecdote that ILC is highly responsive to XRT (despite ~chemoresistance), but do we have the data?

led by Dr. Michael Boysen (now resident at Trinity Health Ann Arbor), w Dr. Corey Speers @ UAB. 🧵1/n

Bronze sculpture of a T-cell attacking a cancer cell.

Bronze sculpture of a T-cell attacking a cancer cell.

Finished another bronze of a T-cell attacking a cancer cell. This one is heading to Max Krummel at UCSF, who did some of the early studies on CTLA4 immunotherapy. #sciart.

Very proud of Sofia for successfully defending her Master’s thesis today!! She’s starting her PhD in biomedicine at UMiami next year. Can’t wait to see what she’ll accomplish! I’m a proud PI!

Thinking about a move from academia to industry? Look before you leap - Nature Biotechnology To those considering a change in careers from academia to the pharmaceutical industry, here are the keys to a successful transition.

A careers feature in Nature Biotechnology provides some keys to a successful transition from a career in academia to one in industry. #Academicsky 🧪

Colorectal cancer treated with cholesterol inhibitor in U. of I. study | School of Molecular & Cellular Biology | Illinois University of Illinois researchers have successfully treated a common type of colorectal cancer tumor with a cholesterol inhibitor drug, demonstrating a promising treatment for the disease in animal experiments.

#Illinois researchers have successfully treated a common type of colorectal cancer tumor with a cholesterol inhibitor drug, demonstrating a promising treatment for the disease in animal experiments.

The study was published in Nature Chemical Biology:

go.mcb.illinois.edu/623
@nelsonlab.bsky.social

We did a thing w @jostrander.bsky.social!
Over the last few years, we took a new direction into #lobular breast cancer oncogenesis. We know loss of the gene CDH1 (E-cadherin) is central to ILC, and is among its earliest oncogenic events. But why? How does this push normal breast toward cancer? 1/n

CDH1 loss remodels gene expression and lineage identity in human mammary epithelial cells https://www.biorxiv.org/content/10.1101/2025.06.20.660633v1

Cool stuff 🎉👏 @mjsikora.bsky.social
@jostrander.bsky.social #bcsm #lobular 🧪🧬

Duckworth statement on Trump’s strikes against Iran nuclear sites.

Duckworth statement on Trump’s strikes against Iran nuclear sites.

Trump bombing Iran was illegal and unjustified.

I ran for Congress to make sure our leaders consider the true costs of war.

And I will be in the Senate, standing on my titanium legs, demanding answers from Trump.

My statement:

Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes. #NEJM

"zimislecel can restore physiologic islet function"

Reference
www.nejm.org/doi/full/10....

Super-resolution microscopy reveals distinct epigenetic states regulated by estrogen receptor activity https://www.biorxiv.org/content/10.1101/2025.06.16.659976v1

HSD3B1 Upregulation via LRH1 Sustains Estrogen Receptor Signaling and Promotes Endocrine Resistance in Breast Cancer Endocrine resistance is a major challenge in the treatment of estrogen receptor-positive (ER+) breast cancer, often leading to disease recurrence and metastasis. 3β-Hydroxysteroid dehydrogenase 1 (3βH...

Congrats Xiuxiu Li on her story out JBC! HSD3B1 Upregulation via LRH1 Sustains Estrogen Receptor Signaling and Promotes Endocrine Resistance in Breast Cancer - Journal of Biological Chemistry @asbmb.bsky.social 🧪https://www.jbc.org/article/S0021-9258%2825%2902255-0/fulltext

Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes | NEJM Zimislecel is an allogeneic stem cell–derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed. We conducted a phase 1–2 study of zimisle...

What an amazing time to be a biomedical scientist.

www.nejm.org/doi/abs/10.1...